Mutations in isocitrate dehydrogenase (IDH) genes are commonly observed in patients with AML, with IDH2 mutations detected at around 10–15% of all patients at AML diagnosis [5, 6]. This evidence concerns the gene IDH1 and acute myeloid leukemia.